Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1999-03-29
2000-11-21
Cook, Rebecca
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
A61K 31585
Patent
active
061503479
ABSTRACT:
This invention discloses a method of using an aldosterone antagonist such as spironolactone, at a dosage which does not disrupt a patient's normal electrolyte and water-retention balance, to inhibit myocardial fibrosis, including left ventricular hypertrophy (LVH).
REFERENCES:
patent: 3013012 (1961-12-01), Cella, et al.
patent: 4003996 (1977-01-01), Pappo et al.
patent: 4081538 (1978-03-01), Ulick
patent: 4559332 (1985-12-01), Grob et al.
patent: 5529992 (1996-06-01), Weber
patent: 5668124 (1997-09-01), Weber
patent: 5668125 (1997-09-01), Weber
K. Weber, et al., "Myocardial Fibrosis, Aldosterone, and Antialdosterone Therapy: Evolving Concepts in the Management of Congestive Heart Failure," Copyrighted 1991 by G.D. Searle & Company, pp. 1-32.
"Highlights Report #1," The XIIIth Congress of the European Society of Cardiology (Amsterdam, The Netherlands), Aug. 1991, pp. 1-4.
C. G. Brilla, et al., "Anti-Aldosterone Treatment and the Prevention of Myocardial Fibrosis in Primary and Secondary Hyperaldosteronism," Journal of Molecular Cellular Cardiology, vol. 25, 1993, pp. 563-575.
C.G. Brilla et al., "Reactive and Reparative Myocardial Fibrosis in Arterial Hypertension in the Rat," Cardiovascular Research, No. 26, vol. 7, Jul. 1992, pp. 671-677.
K. Weber et al., "Factors Associated with Reactive and Reparative Fibrosis of the Myocardium," 4th Gargellen Conference on Cellular and Molecular Alterations in Failing Human Heart, Gargellen, Austria, Basic Res. Cardiol. 87 (Suppl 1), 1992, pp. 291-301.
K. Weber et al., "Myocardial Fibrosis: Role of Ventricular Systolic Pressure, Arterial Hypertension, and Circulating Hormones," 6th Erwin Riesch Symposium, Feudenstadt, Germany Oct. 11-14, 1990, Basic Res Cardiol. 86 (Suppl. 3), 1991 pp. 25-31.
Brilla et al., "Prevention of Myocardial Fibrosis in Hypertension: Role of Fibroblast Corticoid Receptors and Spironolactone," 75th Annual Meeting of Federation of American Societies for Experimental Biology, Atlanta, Georgia, Apr. 21-25, 1991. FASEB (AM SOX EXPO Biol) No. 5, 5136.
Weber et al., "Myocardial Fibrosis: Role of Angiotensin II and Aldosterone," Basic Research in Cardiology 88 (Suppl. 1), 1993, pp. 107-124.
Weber et al., "Myocardial Fibrosis: Functional Significance and Regulatory Factors," Cardiovascular Research vol. 27, No. 3, 1993, pp. 341-348.
Weber et al., "Prevention of Myocardial Fibrosis in Hypertension: Anti-Fibrotic Effects in Spironolactone," European Heart Journal, vol. 12, 1991, 1961, p. 362.
C. G. Brilla et al., "Myocardial Collagen Matrix Remodelling in Arterial Hypertension," European Heart Journal, No. 13, Suppl. D, 1992, pp. 24-32.
K. Weber et al., "Myocardial Fibrosis and the Concepts of Cardioprotection and Cardioreparation," Journal of Hypertension, No. 10, (Suppl. 5), 1992, pp. S87-S94.
K. Weber, et al., Glucocorticoids and Mineralocorticoids: Antifibrotic and Profibrotic Components of Wound Healing, Journal of Laboratory and Clinical Medicine, vol. 120, No. 1, 1992, pp. 22-29.
K. Weber et al., "Myocardial Fibrosis and Elevations in Plasma Aldosterone in Arterial Hypertension," Aldosterone: Fundamental Aspects, vol. 215, 1991, pp. 117-120.
K. Weber, et al., "Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin-Angiotensin-Aldosterone System," Circulation 83:1849, Feb. 5, 1991, pp. 1849-1865.
D. Klug, et al., "Role of Mechanical and Hormonal Factors in Cardiac Remodeling and the Biologic Limits of Myocardial Adaptation," A Symposium: Aldosterone and Antialdosterone Therapy in Cardiovascular Disease, The American Journal of Cardiology, vol. 71, Jan. 21, 1993, pp. 46A-54A.
C. Brilla, et al., "Antifibrotic Effects of Spironolactone in Preventing Myocardial Fibrosis in Systemic Arterial Hypertension," A Symposium: Aldosterone and Antialdosterone Therapy in Cardiovascular Disease, The American Journal of Cardiology, vol. 71, Jan. 21, 1993, pp. 12A-16A.
K. Weber, et al., "Aldosterone and Myocardial Fibrosis in the Rat with Renovascular Hypertension or Hyperaldosteronism," Univ. of Mo., Division of Cardiology, Dec. 12, 1990, 2 pages.
K. Weber, et al., "Myocardial Remodeling and Pathologic Hypertrophy," Hospital Practice, Apr. 15, 1991, pp. 73-80.
K. Weber, et al., "Aldosterone and Antialdosterone Therapy in Congestive Heart Failure," A Symposium: Aldosterone and Antialdosterone Therapy, American Journal of Cardiology, vol. 71, 1993, pp. 3A-11A.
C.G. Brilla, et al., "Aldosterone-Mediated Stimulation of Collagen Synthesis in Cultured Cardiac Fibroblasts," XIVth Congress of the European Society of Cardiology, Aug. 30-Sep. 2, 1992, p. 1421.
C.G. Brilla, et al., "Collagen Metabolism in Cultured Adult Rat Cardiac Fibroblasts: Response to Angiotensin II and Aldosterone,"Journal of Molecular and Cellular Cardiology, vol. 26, No. 7, Jul. 1994, pp. 809-820.
Gduardo, et al., "Endothelial Cell Induced Modulation of Cardiac Fibroblast Collagen Metabolism," Cardiovascular Research, vol. 27, No. 6, 1993, pp. 1004-1008.
Takeda, et al., "Regulation of Aldosterone Synthase in Human Vascular Endothelial Cells by Angiotensin II and Adreno-corticotropin," Journal of Clinical Endocrinology, vol. 81, No. 8, 1996, pp. 2797-2800.
Silvestre, et al., "Myocardial Production of Aldosterone and Corticosterone in the Rat," The Journal of Biological Chemistry, vol. 273, No. 9, Feb. 27, 1998, pp. 4883-4891.
C. Brilla, et al., "Angiotensin II-Mediated Aldosterone Synthesis in Aortic Endothelial Cells," Circulation, vol. 86, No. 4, Suppl. 1, 1992, p. I90.
E. Guarda, et al., "Endothelin-1 Elicits Aldosterone (Aldo) Release from Cultured Endothelial Cells," 1992 Meeting of the Federation of American Societies for Experimental Biology (FASEB), Fed Am Soc Exp Biol Journal, vol. 6, No. 1, 1992, p. 1811.
P. Greenberger, et al., "Readministration of Spironolactone-Intolerant Patient,"NER Allergy Proc., undated, pp. 343-345.
C.G. Brilla, et al., "Renin-angiotensin System and Myocardial Fibrosis in Hypertension: Regulation of the Myocardial Collagen Matrix," European Heart Journal, vol. 14 (Suppl. J), 1993, pp. 57-61.
K. Weber, et al., "Regulatory Mechanisms of Myocardial Hypertrophy and Fibrosis: Results of in vivo Studies," Cardiology, vol. 81 (4-5), 1992, pp. 266-273.
Y. Sun, et al., "Myocardial Fibrosis: Metabolically Active Tissue," Clinical Research, vol. 41, No. 3, Oct. 1993, p. 660.
C.G. Brilla, et al., "Renin-Angiotensin System and Myocardial Collagen Matrix Remodeling in Hypertensive Heart Disease: In Vivo and in Vitro Studies on Collagen Matrix Regulation," Clinical Investigator, No. 71, 1993, pp. S35-S41.
C.G. Brilla, et al., "Inhibition of Collagenase Activity in Cultured Cardiac Fibroblasts by Angiotensin II," XIVth Congress of the European Society of Cardiology, Barcelona, Spain, European Heart Journal, No. 13 (Abstr. Suppl.), Aug. 30-Sep. 1, 1992, p. P700.
G. Zhou, et al., "Angiotensin II-Mediated Stimulation of Collagen Synthesis in Cultured Cardiac Fibroblasts," 1992 Meeting of Federation of American Societies for Experimental Biology, (FASEB), Part II, Anaheim, CA, Fed Am Soc Exp Biol, Journal 6 (5), Apr. 5-9, 1992, A1914, #5661.
L. Matsubara, "Angiotensin II-Mediated Inhibition of Collagenase Activity in Cultured Cardiac Fibroblasts," 1992 Meeting of the Federation of American Societies for Experimental Biology (FASEB), Part I, Anaheim, CA, Fed Am Soc Exp Biol, Journal 6 (4), Apr. 5-9, 1992, A941, #30.
K. Weber, et al., "Cardiac Interstitium: Extracellular Space of the Myocardium," The Heart and Cardiovascular System Scientific Foundations, Second Edition, vols. 1 and 2, 1991, pp. 1465-1480.
K. Weber, et al., "Cardioreparation with Lisinopril in the Management of Hypertension and Heart Failure," Cardiology, vol. 79 (Suppl 1), Jul. 1991, pp. 62-73.
C. Brilla, et al., "Impaired Diastolic Function and Coronary Reserve in Genetic Hypertension Role of Interstitial Fibrosis and Medial Thickening of Intramyocardial Coronary Arteries," Circulation Research, vol. 69 (1), Jul. 1991, pp. 107-115.
C. Brilla, et al., "Cardioreparative Effects of Lisinopril in Rats with Genetic Hypertension and Left Ventricular Hypertrophy," Circulation, vol. 8
Cook Rebecca
The Curators of the University of Missouri
LandOfFree
Use of aldosterone antagonists to inhibit myocardial fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of aldosterone antagonists to inhibit myocardial fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of aldosterone antagonists to inhibit myocardial fibrosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1257297